

Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization

Agenda

17 - 18 April 2018

Centre International de Conférences Genève (CICG), Geneva, Switzerland

Tuesday, 17 April 2018

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
09:30	Welcome – introduction of participants A. CRAVIOTO. Chair of SAGE.		20 min.
09:50	New leadership and new priorities at WHO - Session 1 P. N. SIMELELA. WHO. 20 min. Discussion: 10 min.	FOR INFORMATION	30 min
10:20	Report from Director, IVB and Regional Updates - Session 2 Global report including key updates and challenges from regions. M. FRIEDE. WHO. 30 min.	FOR INFORMATION	1 h 30 min
10:50	Coffee/tea break	Break	30 min.
11:20	Cont. Report from Director, IVB and Regional Updates - Session 2 Discussion: 1 h		
12:20	Report from Gavi, the Vaccine Alliance - Session 3 Report from Gavi, the Vaccine Alliance. S. BERKLEY. Gavi, the Vaccine Alliance. 15 min. Discussion: 25 min.	FOR INFORMATION	40 min.
13:00	Lunch	Break	1h 15 min.
14:15	Malaria Vaccine Implementation Programme (MVIP) - Session 4 Overview of the MVIP F. WERE. MVIP Programme Advisory Group member. 15 min.	FOR INFORMATION Reminder of rationale for SAGE/MPAC Oct 2015 recommendation for pilot implementation; Update on progress of the MVIP; Inform about Programme oversight and advisory	2 h

<p>Current status, pilot country readiness and timelines. G. BONSU, EPI manager in Ghana. 15 min.</p> <p>Discussion: 45 min.</p> <p>Framework for policy decision. M HAMEL. WHO. 15 min.</p> <p>Discussion: 30 min.</p>		<p>bodies; Outline expected timelines to vaccine introduction.</p> <p>Present IVIR-AC feedback on framework; Review of proposed inputs and output measures for modelling. Discuss timelines for framework development.</p>
16:15	Coffee/tea break	Break 30 min.
16:45	<p>Polio the last mile - Session 5</p> <p>Overview of the Global Polio Eradication Initiative. M ZAFFRAN. WHO. 25 min.</p> <p>Polio Post-Certification Strategy. B. BURKHOLDER. WHO. 15 min.</p> <p>Report from SAGE Polio Working Group. P. FIGUEROA. SAGE Polio Working Group Member. 20 min.</p> <p>Discussion: 1h</p>	<p>FOR INFORMATION Current status of the polio eradication program; Update on process of polio eradication certification;</p> <p>FOR DECISION To seek recommendation/endorsement on – proposed Post Certification Strategy; and on revisions to protocol on VDPV outbreak response;</p> <p>2 h</p>
18:45	End of Day	
19:00	Cocktail	

Wednesday, 18 April 2018

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
09:15	<p>Updating policy recommendations on the use of the first licensed dengue vaccine – Session 6</p> <p>Global dengue burden and future projections. A. WILDER-SMITH 5 min.</p> <p>Rationale for SAGE April 2016 recommendations. P. SMITH. SAGE Dengue Working Group Member. 10 min.</p> <p>Long-term safety data stratified by serostatus. P. SMITH. SAGE Dengue Working Group Member. 20 min.</p> <p>Discussion: 15 min.</p>	<p>FOR INFORMATION Rationale for SAGE 2016 recommendations, long-term safety data, attributable risk and absolute risk reduction, benefit risk assessments, ethical considerations</p> <p>FOR DECISION Updating policy recommendations on the use of the dengue vaccine</p>	2 h 30 min.

	Modelling population level vaccine impact and coverage rates. N. FERGUSON. Imperial College, London. 20 min.		
	Discussion: 15 min.		
	Draft recommendations. T. NOLAN. SAGE Dengue Working Group Chair. 5 min.		
	Discussion: 1 h		
11:15	Coffee/tea break	Break	30 min.
11:45	Cont. Updating policy recommendations on the use of the first licensed dengue vaccine – Session 6		
12:15	Reports from other Advisory Committees on Immunization – Session 7	FOR INFORMATION	1 h
	Immunization and Vaccines Related Advisory Committee (IVIR-AC). R. BREIMAN IVIR-AC representative. 10 min.		
	Discussion: 10 min.		
	Expert Committee on Biological Standardization (ECBS). K. CICHUTEK. Chair of ECBS. 10 min.		
	Discussion: 10 min.		
12:55	Lunch	Break	1 h
13:55	Cont. Reports from other Advisory Committees on Immunization – Session 7		
	Global Advisory Committee on Vaccine Safety (GACVS). R. PLESS. Chair of GACVS. 10 min.		
	Discussion: 10 min.		
14:15	Measles and Rubella– Session 8	FOR INFORMATION	2 h
	Session Introduction. N.TURNER. SAGE Measles and Rubella Working Group Chair. 5 min.		
		- Global and regional update	

<p>Global update A. DABBAGH. WHO. 10 min.</p> <p>Discussion: 15 min.</p> <p>The Measles and Rubella Investment Case. K. THOMPSON. Kid Risk Inc. 15 min.</p> <p>Discussion: 20 min.</p> <p>Country classifications for endemic countries. S. REEF. SAGE Measles and Rubella Working Group Member. 25 min.</p> <p>Discussion: 30 min.</p>	<ul style="list-style-type: none"> - Status of mid-term review recommendations - Global Measles and Rubella surveillance update <ul style="list-style-type: none"> - Presentation of an integrated global model and prospective immunization scenario impacts on morbidity and mortality - A roadmap for endemic countries towards closing immunity gaps and achieving elimination - Presentation of the Pros and Cons of methods for assessing age-specific population immunity
16:15 Coffee/tea break	Break 30 min.
<p>16:15 Full Public Health Value Propositions for Vaccines (FPHVPs)- Session 9</p> <p>Session Introduction A. CRAVIOTO. SAGE. 5 min.</p> <p>Concept and status of FPHVP D. KASLOW. Chair of Product Development for Vaccines Advisory Committee (PDVAC). 20 min.</p> <p>Resource allocation issues related to FPHVPs M. JIT. IVIR-AC Member. 15 min.</p> <p>Discussion: 50 min.</p>	<p>FOR INFORMATION 1 h 30 min.</p> <ul style="list-style-type: none"> - The rationale for development of FPHVP for vaccines: priority setting, investment and policy decisions and generating political will - Proposed components in the early vs. late stage FPHVP: objectives and gap analysis - How should FPHVP be used? Stakeholder mapping and customization - Types of economic analysis for FPHVP depending on the budget holder's objectives
18:15 Closing and end of meeting	